Annexon, Inc.

NASDAQ:ANNX

Biotechnology

Healthcare
$3.52 -0.71%

-$0.04 today

Market cap
$576.73M
Beta
1.18
P/E (TTM)
-4.8
EPS (TTM)
-$1.01
52W Low $1.85High $7.18

Volume 2.98M

Average 2.56M

ANNX Total Current Liabilities

All obligations due within one year.

Annexon, Inc.NASDAQ: ANNX

Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total current liabilities rises 7.1% from a year ago

Total current liabilities stood at $35.94M at the end of Q1 FY2026, up 7.1% from a year earlier and down 15.7% from the prior quarter. Over 3 fiscal years it compounded at +24.0% a year.

Context

  • Total current liabilities amounted to 13.7% of total assets at the end of Q1 FY2026, up 2.6 pp from a year earlier.
  • Total current liabilities increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total current liabilities keeps rising in the next quarterly balance sheet after a +7.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$35.94M-15.7% QoQ
Last fiscal yearDec 2025
$42.63M+39.7% YoY
Year agoMar 2025
$33.55M+7.1% since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.1%——
1 year+39.7%——
3-year CAGR+24.0%——
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
42.63M USD
Year-over-year change
+39.7%
4-year CAGR
+18.3%

Total Current Liabilities vs competitors

How ANNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +7.1% is the 3rd highest of 11, against a peer median of -12.9%.
  • Total current liabilities amounts to 13.7% of total assets for ANNX, versus a peer median of 13.7%.
ANNX Competitors
Total Current Liabilities for ANNX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMVTImmunovant, Inc.Sep 2026$104.02M USD+64.5%+34.1%13.7%
ACIUAC Immune S.A.Mar 2026CHF 92.25M CHF-7.1%+102.1%67.1%
XNCRXencor, Inc.Jun 2026$81.87M USD-14.8%+14.5%11.3%
ALMSAlumis Inc. Common StockJun 2026$76.23M USD-10.9%+76.4%13.6%
ABVXAbivax S.A.Jun 2026€71.69M EUR-36.2%+7.0%15.5%
ANABAnaptysBio, Inc.Mar 2026$41.7M USD-5.3%+14.0%12.6%
ANNXAnnexon, Inc.Mar 2026$35.94M USD+7.1%+24.0%13.7%
PRTAProthena Corporation plcMar 2026$32.52M USD-32.9%-6.6%9.3%
ACRSAclaris Therapeutics, Inc.Mar 2026$27.37M USD+27.2%+9.3%13.8%
IFRXInflaRx N.V.Mar 2026€11.4M EUR-29.6%-0.1%23.3%
QTTBQ32 Bio Inc.Mar 2026$10.67M USD-26.8%-41.9%16.8%
Peer median (excluding ANNX) —-12.9%+11.7%13.7%

Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents74.84M140.02M225.11M49.5M162.05M
Short-term Investments167.87M102.64M34.61M262.52M76.29M
Net Receivables00000
Inventory00000
Other Current Assets463K203K63K1.1M1.24M
Total Current Assets247.69M248.1M263.86M316.46M242.19M
Property, Plant & Equipment (Net)38.18M35.97M32.78M29.34M25.8M
Goodwill00000
Intangible Assets00000
Long-term Investments01.03M000
Tax Assets00000
Other Non-current Assets1.17M1.03M1.03M4.27M9.58M
Total Non-current Assets39.35M37M33.81M33.61M35.38M
Total Assets287.04M285.1M297.67M350.07M277.57M
Account Payables11.15M7.42M5.49M10.43M14.93M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities2.06M180K5.65M5.97M8.03M
Total Current Liabilities21.74M22.36M17.93M30.51M42.63M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities33.39M31.54M29.19M26.45M23.29M
Total Liabilities55.13M53.9M47.12M56.97M65.92M
Common Stock39K48K78K109K149K
Retained Earnings(296.32M)(438.26M)(572.5M)(710.7M)(917.39M)
Accumulated OCI(180K)(372K)(52K)10K(29K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity231.91M231.19M250.56M293.11M211.65M
Total Debt34.59M32.86M31.36M28.97M26.2M
Net Debt(40.25M)(107.16M)(193.76M)(20.53M)(135.85M)

Annexon, Inc.

NASDAQ:ANNX

Intrinsic Alpha fair value

Locked

Current Price

$3.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.